Ultraviolet C light efficiently inactivates nonenveloped hepatitis A virus and feline calicivirus in platelet concentrates

Transfusion

Volumn 58, Issue 11, 2018, Pages 2669-2674

  Gravemann, Ute ^a   Handke, Wiebke ^a   Lambrecht, Bernd ^a   Schmidt, Jörg Peter ^b   Müller, Thomas H ^a   Seltsam, Axel ^a  

^a Institute Springe   (Germany)

^b German Red Cross Blood Transfusion Service NSTOB   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; FELINE CALICIVIRUS; HEPATITIS A VIRUS; HUMAN CELL; INFECTIOUS AGENT; LIMIT OF DETECTION; NONHUMAN; STEM CELL CULTURE; THROMBOCYTE; ULTRAVIOLET C RADIATION; VIRUS INFECTIVITY; VIRUS LOAD; ANIMAL; CAT; CELL LINE; HUMAN; RADIATION RESPONSE; ULTRAVIOLET RADIATION; VIROLOGY;

ANIMALS; BLOOD PLATELETS; CALICIVIRUS, FELINE; CATS; CELL LINE; HEPATITIS A VIRUS; HUMANS; ULTRAVIOLET RAYS;

EID: 85054062648     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14957     Document Type: Article

References (48)

1. Robertson BH, Erdman DD. Non-enveloped viruses transmitted by blood and blood products. Dev Biol 2000;102:29-35
2. Parsyan A, Candotti D. Human erythrovirus B19 and blood transfusion—an update. Transfus Med 2007;17:263-78
3. Kwon SY, Kim IS, Bae JE, et al. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 2014;107:254-60
4. Hauser L, Roque-Afonso AM, Beyloune A, et al. Hepatitis E transmission by transfusion of intercept blood system-treated plasma. Blood 2014;123:796-7
5. Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006;46:1168-77
6. Domanovic D, Tedder R, Blumel J, et al. Hepatitis E and blood donation safety in selected European countries: a shift to screening? Euro Surveill 2017;22:1–8
7. Mohr H, Steil L, Gravemann U, et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009;49:2612-24
8. Seltsam A, Muller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011;38:43-54
9. Seltsam A, Muller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013;162:442-54
10. Douki T, Laporte G, Cadet J. Inter-strand photoproducts are produced in high yield within A-DNA exposed to UVC radiation. Nucleic Acids Res 2003;31:3134-42
11. Faddy HM, Fryk JJ, Prow NA, et al. Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 2016;56:1548-55
12. Fryk JJ, Marks DC, Hobson-Peters J, et al. Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light. Transfusion 2017;57:2677-82
13. Castro E, Gonzalez LM, Rubio JM, et al. The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion 2014;54:2207-16
14. Mohr H, Gravemann U, Bayer A, et al. Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009;49:1956-63
15. Eickmann M, Gravemann U, Handke W, et al. Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. Transfusion 2018;58:2202-7
16. Epstein JS, Vostal JG. FDA approach to evaluation of pathogen reduction technology. Transfusion 2003;43:1347-50
17. World Health Organization. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO Technical Report Series No. 924: Annex 4. Geneva: WHO; 2004
18. Meyers JD, Huff JC, Holmes KK, et al. Parenterally transmitted hepatitis A associated with platelet transfusions. Epidemiologic study of an outbreak in a marrow transplantation center. Ann Intern Med 1974;81:145-51
19. Meyers JD, Dienstag JL, Purcell RH, et al. Parenterally transmitted non-A, non-B hepatitis: an epidemic reassessed. Ann Intern Med 1977;87:57-9
20. Skidmore SJ, Boxall EH, Ala F. A case report of post-transfusion hepatitis A. J Med Virol 1982;10:223
21. Sherertz RJ, Russell BA, Reuman PD. Transmission of hepatitis A by transfusion of blood products. Arch Intern Med 1984;144:1579-80
22. Hughes JA, Fontaine MJ, Gonzalez CL, et al. Case report of a transfusion-associated hepatitis A infection. Transfusion 2014;54:2202-6
23. da Silva SG, Leon LA, Alves G, et al. A rare case of transfusion transmission of hepatitis A virus to two patients with haematological disease. Transfus Med Hemother 2016;43:137-41
24. Farcet MR, Lackner C, Antoine G, et al. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes. Transfusion 2016;56:383-91
25. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Gesamtnovelle 2005 mit Richtlinienanpassung 2010 ed. Köln: Deutscher Ärzte; 2010
26. Eriksson L, Shanwell A, Gulliksson H, et al. Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies. Vox Sang 1993;64:133-8
27. Gulliksson H, Larsson S, Kumlien G, et al. Storage of platelets in additive solutions: effects of phosphate. Vox Sang 2000;78:176-84
28. Servant-Delmas A, Morinet F. Update of the human parvovirus B19 biology. Transfus Clin Biol 2016;23:5-12
29. Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014;384:1766-73
30. U.S. Food and Drug Administration. Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Fed Register 1998;63:51074-84
31. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49(Suppl 2):1S-29S
32. Ankcorn MJ, Tedder RS. Hepatitis E: the current state of play. Transfus Med 2017;27:84-95
33. Matsubayashi K, Nagaoka Y, Sakata H, et al. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion 2004;44:934-40
34. Matsubayashi K, Kang JH, Sakata H, et al. A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 2008;48:1368-75
35. Boxall E, Herborn A, Kochethu G, et al. Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transfus Med 2006;16:79-83
36. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System. Transfus Med Hemother 2011;38:19-31
37. Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011;38:8-18
38. Keil SD, Bengrine A, Bowen R, et al. Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment. Transfusion 2015;55:1736-44
39. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45:580-90
40. Sawyer L, Hanson D, Castro G, et al. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007;47:1062-70
41. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004;44:877-85
42. Owada T, Kaneko M, Matsumoto C, et al. Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system. Transfusion 2014;54:2820-7
43. Hanson CV. Photochemical inactivation of viruses with psoralens: an overview. Blood Cells 1992;18:7-25
44. Shukla P, Nguyen HT, Faulk K, et al. Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J Virol 2012;86:5697-707
45. Normann A, Jung C, Vallbracht A, et al. Time course of hepatitis A viremia and viral load in the blood of human hepatitis A patients. J Med Virol 2004;72:10-6
46. Dreier J, Juhl D. Autochthonous hepatitis E virus infections: a new transfusion-associated risk? Transfus Med Hemother 2014;41:29-39
47. Dreier J, Knabbe C, Vollmer T. Transfusion-transmitted hepatitis E: NAT screening of blood donations and infectious dose. Front Med 2018;5:5
48. Kapsch AM, Farcet MR, Antoine G, et al. A nonenveloped virus with a lipid envelope: hepatitis A virus as used in virus-reduction studies. Transfusion 2017;57:1433-9